Quest for the right Drug

|
עמוד הבית / קומאגיס קרם / מידע מעלון לרופא

קומאגיס קרם COMAGIS CREAM (BIFONAZOLE, FLUOCINONIDE)

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

עורי : DERMAL

צורת מינון:

קרם : CREAM

Special Warning : אזהרת שימוש

4.4   Special warnings and precautions for use

This product contains cetostearyl alcohol which may cause local skin reactions (e.g.
contact dermatitis).
This product contains Benzyl alcohol which may cause allergic reactions and mild local irritation.

Patients with a history of hypersensitivity reactions to other imidazole antifungal agents (e.g. econazole, clotrimazole, miconazole) must take bifonazole containing products with caution.
Systemic absorption of topical corticosteroids has produced reversible hypothalamic- pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.
Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.
Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.
Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug.
Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.
Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. (See Pediatric Use). If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.
As with any topical corticosteroid product, prolonged use may produce atrophy of the skin and subcutaneous tissues. When used on intertriginous or flexor areas, or on the face, this may occur even with short-term use.
In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

Pediatric use

Pediatric patients may demonstrate greater susceptibility to topical corticosteroid- induced Hypothalamic-pituitary-adrenal (HPA) axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio.
HPA axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.


Effects on Driving

4.7   Effects on ability to drive and use machines
The medication has no or negligible influence on the ability to drive or use machinery.


שימוש לפי פנקס קופ''ח כללית 1994 לא צוין
תאריך הכללה מקורי בסל לא צוין
הגבלות לא צוין

רישום

063 04 26742 00

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

22.07.21 - עלון לרופא 07.06.23 - עלון לרופא

עלון מידע לצרכן

25.10.21 - עלון לצרכן אנגלית 25.10.21 - עלון לצרכן עברית 25.10.21 - עלון לצרכן ערבית 07.06.23 - עלון לצרכן עברית 20.12.23 - עלון לצרכן עברית 30.12.23 - עלון לצרכן אנגלית 30.12.23 - עלון לצרכן ערבית 23.03.14 - החמרה לעלון 17.05.16 - החמרה לעלון 22.07.21 - החמרה לעלון

לתרופה במאגר משרד הבריאות

קומאגיס קרם

קישורים נוספים

RxList WebMD Drugs.com